# A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Source: https://onco.cc/trials/nct02586857/  
OnCo record `nct02586857` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ACP-196 in glioma & glioblastoma, run by Acerta Pharma BV, active and no longer recruiting.

## Summary

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) is a phase 1/2 interventional study registered as NCT02586857 by Acerta Pharma BV, with 24 participants enrolled, started 2016-01-25 and due to reach its primary completion in 2020-06-26. Interventions recorded: ACP-196. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02586857
- Phase: 1/2
- Setting: A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
- Sponsor: Acerta Pharma BV
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT02586857: https://clinicaltrials.gov/study/NCT02586857

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct02586857.json